Tirzepatide vs Mazdutide

Tirzepatide and Mazdutide represent two advanced peptide-based strategies in metabolic research, each targeting distinct receptor pathways to address obesity and related disorders. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated robust clinical efficacy, while Mazdutide, a GLP-1/glucagon receptor agonist, introduces a novel mechanism that may enhance energy expenditure and hepatic fat reduction. This comparison highlights their mechanistic differences, evidence bases, dosing regimens, and safety considerations, providing researchers with a comprehensive framework for selecting the appropriate tool for specific study objectives.

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that facilitates albumin binding, enabling once-weekly dosing. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), including severe obstructive sleep apnea in adults with obesity, it has shown superior weight reduction in clinical trials, with up to 22.5% mean body weight loss at 72 weeks. Research suggests it improves glycemic control and may reduce liver fat in non-alcoholic steatohepatitis (NASH), though further studies are needed to confirm these benefits.

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly (MW 4,563.06 g/mol). It is a once-weekly injectable peptide that activates both GLP-1 and glucagon receptors, aiming to combine GLP-1-mediated appetite suppression and glucose lowering with glucagon-mediated increases in energy expenditure and hepatic fat reduction. China's NMPA approved mazdutide in June 2025 for chronic weight management and in September 2025 for glycaemic control in type 2 diabetes, making it the first dual GLP-1/glucagon agonist approved anywhere in the world.

Key claims: Significant weight loss in Chinese adults with obesity; Effective glycemic control; Reduces hepatic fat content.

Both Tirzepatide and Mazdutide are primarily investigated for weight management and metabolic health, including obesity and type 2 diabetes. Tirzepatide's additional research applications are not specified beyond these core areas, while Mazdutide similarly focuses on metabolic conditions. Researchers may explore their distinct mechanisms to compare effects on energy balance, glucose homeostasis, and hepatic steatosis, though no unique applications beyond weight and metabolic health are documented in the provided data.

Tirzepatide: Common adverse events (≥5% in trials) include abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, and vomiting. Serious but rare risks include pancreatitis, gallbladder events, and dehydration leading to kidney problems. An FDA boxed warning highlights thyroid C-cell tumors in rodent studies; patients should monitor for neck lump, swallowing difficulty, hoarseness, or shortness of breath. Mazdutide: Common gastrointestinal side effects (nausea, vomiting, diarrhea) are dose-dependent and generally transient, consistent with GLP-1 agonist class effects. Heart rate increases have been observed, aligning with GLP-1 agonist mechanisms. No boxed warnings are noted, but ongoing surveillance is warranted.